1/6/2014

RadioMedix announced it has received orphan drug status from the FDA for 68Ga-DOTATATE, or GalioMedix, a PET/CT agent for neuroendocrine tumor imaging. Preliminary tests have showed higher sensitivity and image resolution and rapid results with the new agent.

Full Story:
PRWeb

Related Summaries